In Depth 14 Mar 2024
Rett syndrome: advances in gene therapy brings hope
Explore the latest advancements in treating Rett syndrome, a rare genetic disorder, including groundbreaking gene therapies and drug trials.
Neurological disorders
- Latest Posts
Podcast 23 Feb 2024
Precision neuromedicine: A new dawn for neurological disorders
This week on our podcast, explore how precision neuromedicine is reshaping neurological care with Rapport Therapeutics.
In Depth 31 Jan 2024
New epilepsy drugs: what is in the pipeline?
Find out about the new epilepsy drugs currently in the pipeline, as resistance to current AEDs underscores the need for new treatments.
News and Trends 18 Jan 2024
2024 J.P. Morgan Healthcare Conference: key takeaways from the largest biotech gathering of the year
Here are some of the key takeaways from the JPM Healthcare Conference that lay the groundwork for what we can expect in 2024.
Best in Biotech 14 Dec 2023
Seven companies shaping the future of precision medicine
Explore the forefront of healthcare innovation with these seven cutting-edge biopharma companies specializing in precision medicine.
News and Trends 31 Jul 2023
Biogen acquiring Reata Pharmaceuticals for $7.3B
Biogen Inc. and Reata Pharmaceuticals, Inc. have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Reata has made advancements developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Reata’s FDA-approved SKYCLARYS (omaveloxolone) is […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 26 Jun 2023
AbbVie takes step forward in Europe with migraine drug
AbbVie says the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CMHP) has adopted a positive opinion recommending the approval of atogepant for the prophylaxis of migraine in adults who have four or more migraine days per month. If approved, AbbVie will be the only company to offer a once daily oral […]
News and Trends 23 Jun 2023
New disease characteristic seen as NMD Pharma reports Charcot-Marie-Tooth results
NMD Pharma A/S, a clinical stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, has presented results from ESTABLISH1, an observational study of neuromuscular function in patients with the inherited neurological conditions Charcot-Marie-Tooth (CMT) types 1 and 2. The results were revealed in a poster presentation at the Peripheral Nerve Society Annual […]
News and Trends 25 May 2023
PharmEnable raises $7.5M to develop small molecule drugs to treat cancer and neurological diseases
PharmEnable, a drug discovery company focused on chemical novelty, diversity and complexity, announces it has closed a Pre-Series A investment round of $7.5M to develop the next generation of small molecule drugs against disease areas of high clinical need. The funding round was led by MP Healthcare Venture Management (MPH), the venture arm of Mitsubishi […]
News and Trends 18 May 2023
New epilepsy study could lead to new treatment options
The mechanisms underlying the pathogenesis of epilepsy, a neurological disorder characterized by excessive electrical activity in the brain, remain unknown. Now, using a novel radiotracer, researchers from Japan have been able to offer insight into the role of AMPAR trafficking in epileptogenesis. The radio tracer is [11C]K-2, the first technology to visualize and quantify α-amino-3-hydroxy-5-methyl-4-isoxazole […]
News and Trends 18 May 2023
Sania Therapeutics launches to advance neural circuit dysfunction medicines
Sania Therapeutics, which develops genetic medicines for neural circuit dysfunction, has launched with the unveiling of its platforms at the American Society of Gene & Cell Therapy (ASGCT) conference. Sania Therapeutics’ approach combines the evolution of adeno-associated viruses (AAV) in human neural circuits, the fundamental components of the nervous system, and tuneable conditionally-activated ion channels. […]
Best in Biotech 12 May 2023
Five latest advancements in Tourette’s syndrome research
Named after French neurologist Georges Gilles de la Tourette, who first described the disorder in 1885, Tourette’s syndrome is estimated to affect one in 10 to 1000 people worldwide. A neurological condition, the disorder causes involuntary movements and sounds, commonly known as tics. Although its exact cause isn’t known, research points to a link between […]
ADVERTISEMENT
